BackIonis Pharmaceuticals Overview

Ionis Pharmaceuticals Net Tangible Assets

Latest net tangible assets for IONS: $440M.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$439.74M
30.42% YoYΔ $-192.26M vs prior year quarter

Peer trimmed avg / median

Loading

Ionis Pharmaceuticals Net Tangible Assets History

Loading

Ionis Pharmaceuticals vs. peers: Net Tangible Assets Comparison

Loading

Ionis Pharmaceuticals Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ionis Pharmaceuticals (IONS) FAQ

Ionis Pharmaceuticals (IONS) currently reports a net tangible assets of $440M as of June 2026. That compares with $630M in the prior-year period — down 30.4% year over year. Use the charts on this page to explore Ionis Pharmaceuticals's net tangible assets history and peer comparisons.

Ionis Pharmaceuticals's net tangible assets decreased from $630M to $440M — a 30.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ionis Pharmaceuticals reported $440M in net tangible assets as of June 2026. That compares with $630M in the prior-year period — down 30.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $440M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ionis Pharmaceuticals, and consider following IONS for alerts when major investors trade the stock.

Ionis Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $440M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IONS with unrelated industries.